Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > 2020 PWC Going Concern reports, the company burns thru 300k

<< Previous

Bullboard Posts

Next >>

Comment by biotraderpro1on May 04, 2021 7:51pm

255 Views

Post# 33129323

RE:2020 PWC Going Concern reports, the company burns thru 300k

This is jargon written into every financial report. If that concerns you, then maybe high risk penny stocks are not for you.

Also, The fact that a director of the company loaned the company over 2.5 mill ( through debentures) should speak to the confidence of the lender to at least get his money back. .... Not to mention the other money raised recently.

Never an easy ride but if results are good, we should be rewarded.

GLTA

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China